Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche’s cancer drug “brings new hope”

Roche’s cancer drug “brings new hope”

11th November 2008

Roche’s lung cancer drug Tarceva (erlotinib) has been shown to delay progression of the disease, the company has announced.

The Saturn (SequentiAl Tarceva in UnResectable NSCLC) study found the drug – when administered immediately after initial platinum-based chemotherapy treatment – "significantly extended" the lives of patients with advanced non-small cell lung cancer (NSCLC) without the disease progressing.

Roche said the Saturn study’s results were significant to physicians and patients of NSCLC, which accounts for nearly 80 per cent of all lung cancers.

Trial investigator, Professor F Cappuzzo, MD from the Istituto Clinico Humanitas IRCCS in Milan, said: "Lung cancer patients need options to stop the rapid progress of this disease without the side effects of chemotherapy."

The study revealed the drug "provides this option and gives new hope to patients and their families," he added.

Following a full analysis of the Saturn results, the study will be presented at a medical meeting in the future.

People in scientific sales jobs may be interested in Roche’s range of pharmaceuticals, which includes MabThera and Tamiflu.


We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.